Earnings summaries and quarterly performance for Alzamend Neuro.
Executive leadership at Alzamend Neuro.
Board of directors at Alzamend Neuro.
Research analysts covering Alzamend Neuro.
Recent press releases and 8-K filings for ALZN.
Alto Neuroscience Faces Class Action Lawsuit Over ALTO-100 Trial Results
ALZN
Legal Proceedings
Profit Warning
- A class action lawsuit has been filed against Alto Neuroscience, Inc. (NYSE: ANRO) on behalf of investors who purchased securities between February 2, 2024, and October 22, 2024.
- The lawsuit alleges that Alto Neuroscience made false or misleading statements regarding the effectiveness of its drug candidate, ALTO-100, for treating major depressive disorder (MDD), overstating its clinical, regulatory, and commercial prospects.
- On October 22, 2024, Alto Neuroscience announced that ALTO-100 did not meet its primary endpoint in a Phase 2b trial for MDD, leading to a nearly 70% drop in the company's stock price.
- Investors have until September 19, 2025, to file a lead plaintiff motion in the class action lawsuit.
Sep 3, 2025, 8:44 PM
Alto Neuroscience, Inc. Faces Class Action Lawsuit
ALZN
Legal Proceedings
Profit Warning
- A class action lawsuit has been filed against Alto Neuroscience, Inc. (NYSE: ANRO) for investors who purchased securities between February 2, 2024 and October 22, 2024.
- The lawsuit alleges that the company made false or misleading statements regarding its drug candidate, ALTO-100, which was less effective in treating Major Depressive Disorder (MDD) than represented, and that its prospects were overstated.
- On October 22, 2024, Alto Neuroscience announced that ALTO-100's Phase 2b trial did not meet its primary endpoint, causing the stock to fall nearly 70%.
- Investors have until September 19, 2025 to file a lead plaintiff motion.
Aug 29, 2025, 8:20 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more